FDA Approval Status of Retatrutide for Weight Loss Expected by 2026 | Retatrutide News

Retatrutide, a GLP-1 agonist from Eli Lilly, is expected to receive FDA approval by 2026 for weight loss. This development is significant for the treatm...
Market News · October 19, 2026